Crinetics Pharmaceuticals Inc

Common Name

Crinetics Pharmaceuticals

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

437

Ticker

CRNX

Exchange

NASDAQ/NGS

Website

www.crinetics.com

Description

Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Cr... Show more

Financial Statements of Crinetics Pharmaceuticals

Below are the financial statements of Crinetics Pharmaceuticals, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	264.55^a	54.9^a
Restricted cash	0.5^a	0^a
Investment securities, amortized cost of $1,088,561 at December 31, 2024 and $502,681 at December 31, 2023	1,089.52^a	503.66^a
Prepaid expenses and other current assets	20.82^a	15.6^a
Assets	—	—
Total current assets	1,375.39^a	574.15^a
Property and equipment, net	12.07^a	10.88^a
Operating lease right-of-use assets	43.51^a	46.55^a
Investment in Radionetics	0^a	0.47^a
Restricted cash, net of current portion	0.8^a	1.3^a
Other assets	2.83^a	2^a
Total assets	1,434.59^a	635.35^a
Current liabilities	—	—
Accounts payable and accrued expenses	21.47^a	23.2^a
Accrued compensation and related expenses	28.89^a	14.52^a
Deferred revenue	2.18^a	2.06^a
Operating lease liabilities	7.15^a	4.17^a
Liabilities and stockholders’ equity	—	—
Total current liabilities	59.68^a	43.94^a
Operating lease liabilities, non-current	44.57^a	47.56^a
Deferred revenue, non-current	4.7^a	4.75^a
Other non-current liabilities	0.83^a	0^a
Total liabilities	109.79^a	96.25^a
Stockholders’ equity	—	—
Preferred stock	0^a	0^a
Common stock and paid-in capital	2,275.95^a	1,191.83^a
Accumulated other comprehensive income (loss)	0.96^a	0.98^a
Accumulated deficit	-952.11^a	-653.7^a
Total stockholders’ equity	1,324.81^a	539.11^a
Total liabilities and stockholders’ equity	1,434.59^a	635.35^a

Verified Sources Behind Crinetics Pharmaceuticals’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Crinetics Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.

a. Crinetics Pharmaceuticals's 10-K 2024

Trace every data point back to Crinetics Pharmaceuticals’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Crinetics Pharmaceuticals Inc

Financial Statements of Crinetics Pharmaceuticals

Verified Sources Behind Crinetics Pharmaceuticals’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

BioMarin Pharmaceutical Inc

Vericel Corp

Blueprint Medicines Corp

Immunovant Inc

Ultragenyx Pharmaceutical Inc

Cytokinetics Inc